CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 316,231,000	$ 316,727,000
Marketable securities	229,983,000	0
Trade receivables, net	79,522,000	0
Inventories	20,131,000	0
Prepaid expenses and other current assets	62,418,000	11,554,000
Total current assets	708,285,000	328,281,000
Property and equipment, net	8,802,000	8,152,000
Equity method investment	1,866,000	5,338,000
Intangible assets, net	39,811,000	0
Other assets	23,251,000	2,493,000
Total assets	782,015,000	344,264,000
Current liabilities:
Accounts payable	43,976,000	14,071,000
Accrued expenses and other current liabilities	126,267,000	52,102,000
Current portion of mandatorily redeemable preferred shares	46,875,000	0
Total current liabilities	217,118,000	66,173,000
Long-term debt	264,135,000	0
Liability related to sale of future royalties, net	318,594,000	144,111,000
Mandatorily redeemable preferred shares, net	119,456,000	103,646,000
Derivative liabilities	1,940,000	37,690,000
Other long-term liabilities	14,590,000	68,000
Total liabilities	935,833,000	351,688,000
Commitments and contingencies
Contingently redeemable non-controlling interests	60,000,000	0
Shareholders’ Equity (Deficit):
Common shares, no par value; 200,000,000 shares authorized as of September 30, 2020 and December 31, 2019; 59,707,780 and 52,385,283 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively	1,205,384,000	881,426,000
Additional paid-in capital	103,419,000	83,523,000
Accumulated other comprehensive income	251,000	0
Accumulated deficit	(1,521,433,000)	(972,373,000)
Total shareholders’ equity (deficit) attributable to Biohaven Pharmaceutical Holding Company Ltd.	(212,379,000)	(7,424,000)
Non-controlling interests	(1,439,000)	0
Total shareholders' equity (deficit)	(213,818,000)	(7,424,000)
Total liabilities and shareholders' equity (deficit)	$ 782,015,000	$ 344,264,000